FDA’s in-house review offers bleak assessment of Epizyme’s tazemetostat — but win or lose this cancer drug may still have a future
Epizyme will have to overcome a tough assessment from the FDA’s in-house review team for their cancer drug tazemetostat if they expect to make it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
